BRIEF-DRI Healthcare Buys Synthetic Royalty Interest In Sales Of Sebetralstat For Hereditary Angioedema Treatment

Reuters11-04

Nov 4 (Reuters) - Dri Healthcare Trust :

* DRI HEALTHCARE TRUST ANNOUNCES ACQUISITION OF A SYNTHETIC ROYALTY INTEREST IN THE WORLDWIDE SALES OF SEBETRALSTAT FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA PLUS AN EQUITY INVESTMENT IN KALVISTA PHARMACEUTICALS

* DRI HEALTHCARE TRUST - ROYALTY INTEREST ACQUIRED FOR UP TO $179 MILLION

* DRI HEALTHCARE TRUST - FDA SETS PDUFA DATE FOR SEBETRALSTAT ON JUNE 17, 2025

* DRI HEALTHCARE TRUST - INVESTS $5 MILLION IN KALVISTA STOCK

* DRI HEALTHCARE TRUST - KALVISTA ENTITLED TO $50 MILLION MILESTONE PAYMENT

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480587867?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 23:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480587867","market":"us","top_or_hot":-1,"title":"BRIEF-DRI Healthcare Buys Synthetic Royalty Interest In Sales Of Sebetralstat For Hereditary Angioedema Treatment","media":"Reuters","content":"<html><body><p>Nov 4 (Reuters) - Dri Healthcare Trust   :</p><p>   * DRI HEALTHCARE TRUST ANNOUNCES ACQUISITION OF A SYNTHETIC ROYALTY INTEREST IN THE WORLDWIDE SALES OF SEBETRALSTAT FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA PLUS AN EQUITY INVESTMENT IN KALVISTA PHARMACEUTICALS</p><p>   * DRI HEALTHCARE TRUST - ROYALTY INTEREST ACQUIRED FOR UP TO $179 MILLION</p><p>   * DRI HEALTHCARE TRUST - FDA SETS PDUFA DATE FOR SEBETRALSTAT ON JUNE 17, 2025</p><p>   * DRI HEALTHCARE TRUST - INVESTS $5 MILLION IN KALVISTA STOCK</p><p>   * DRI HEALTHCARE TRUST - KALVISTA ENTITLED TO $50 MILLION MILESTONE PAYMENT</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-DRI Healthcare Buys Synthetic Royalty Interest In Sales Of Sebetralstat For Hereditary Angioedema Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-DRI Healthcare Buys Synthetic Royalty Interest In Sales Of Sebetralstat For Hereditary Angioedema Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 23:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 4 (Reuters) - Dri Healthcare Trust   :   * DRI HEALTHCARE TRUST ANNOUNCES ACQUISITION OF A SYNTHETIC ROYALTY INTEREST IN THE WORLDWIDE SALES OF SEBETRALSTAT FOR THE TREATMENT OF HEREDITARY ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HCSG","symbol_name":"医疗保健服务","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2480587867","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480587867","pubTimestamp":1730733555,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 4  - Dri Healthcare Trust   :   * DRI HEALTHCARE TRUST ANNOUNCES ACQUISITION OF A SYNTHETIC ROYALTY INTEREST IN THE WORLDWIDE SALES OF SEBETRALSTAT FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA PLUS AN EQUITY INVESTMENT IN KALVISTA PHARMACEUTICALS   * DRI HEALTHCARE TRUST - ROYALTY INTEREST ACQUIRED FOR UP TO $179 MILLION   * DRI HEALTHCARE TRUST - FDA SETS PDUFA DATE FOR SEBETRALSTAT ON JUNE 17, 2025   * DRI HEALTHCARE TRUST - INVESTS $5 MILLION IN KALVISTA STOCK   * DRI HEALTHCARE TRUST - KALVISTA ENTITLED TO $50 MILLION MILESTONE PAYMENTSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HCSG":"医疗保健服务","DRI":"达登饭店"},"translate_title":"简介-DRI Healthcare购买用于治疗遗传性血管性水肿的Sebetralstat销售的合成特许权使用费权益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRI":1,"HCSG":1},"content_text":"Nov 4 (Reuters) - Dri Healthcare Trust   :   * DRI HEALTHCARE TRUST ANNOUNCES ACQUISITION OF A SYNTHETIC ROYALTY INTEREST IN THE WORLDWIDE SALES OF SEBETRALSTAT FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA PLUS AN EQUITY INVESTMENT IN KALVISTA PHARMACEUTICALS   * DRI HEALTHCARE TRUST - ROYALTY INTEREST ACQUIRED FOR UP TO $179 MILLION   * DRI HEALTHCARE TRUST - FDA SETS PDUFA DATE FOR SEBETRALSTAT ON JUNE 17, 2025   * DRI HEALTHCARE TRUST - INVESTS $5 MILLION IN KALVISTA STOCK   * DRI HEALTHCARE TRUST - KALVISTA ENTITLED TO $50 MILLION MILESTONE PAYMENTSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480587867"}